{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:23:43Z","timestamp":1787163823259,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Phosphodiesterase type-5 inhibitors (PDE5i) are widely used as first-line therapy for erectile dysfunction (ED). Traditionally, they have been viewed primarily as symptomatic agents that facilitate erections during sexual activity. However, extensive clinical experience suggests that their role in erectile medicine extends beyond simple pharmacologic facilitation of erection. In everyday practice, the response to PDE5i provides valuable physiological information about the erectile system. The magnitude and quality of erectile response often reflect underlying penile hemodynamics, cavernosal smooth muscle function, and the integrity of the veno-occlusive mechanism. Thus, the clinical response to PDE5i may function as a practical indicator of erectile reserve, initiating the diagnostic process in ED. Furthermore, PDE5i appear to enhance responsiveness to other therapeutic modalities and support cavernosal tissue oxygenation during chronic use. Based on these clinical observations, PDE5i may be conceptualized as fulfilling three complementary roles: initiators of erectile activity, enablers of multimodal therapy, and sustainers of cavernosal tissue health. This conceptual framework aims to integrate pharmacologic action with clinical interpretation and therapeutic strategy in sexual medicine.<\/jats:p>","DOI":"10.1038\/s41443-026-01329-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:53:10Z","timestamp":1784541190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond symptomatic treatment: PDE5 inhibitors as initiators, enablers, and sustainers of erectile function"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-3965","authenticated-orcid":false,"given":"Dimitris","family":"Hatzichristou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/sxmrev\/qeaf035","volume":"13","author":"N Stern","year":"2025","unstructured":"Stern N, Bajic P, Campbell J, Capogrosso P, Domes T, Miranda EP, et al. Evolving medical management of erectile dysfunction: recommendations from the fifth international consultation on sexual medicine (ICSM 2024). Sex Med Rev. 2025;13:513\u201337.","journal-title":"Sex Med Rev"},{"key":"1329_CR2","doi-asserted-by":"publisher","unstructured":"Zhang Y, Peng H, Xin S, Mao M, Zhang J, Li H, et al. Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trials. Syst Rev. 2025;15:35. https:\/\/doi.org\/10.1186\/s13643-025-03042-4","DOI":"10.1186\/s13643-025-03042-4"},{"key":"1329_CR3","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.21037\/tau-2025-581","volume":"14","author":"K Zhong","year":"2025","unstructured":"Zhong K, Hu H, Xiao L, Fan G, Zhang L. Vascular aging-driven erectile dysfunction: pathophysiological mechanisms and emerging therapies-a narrative review. Transl Androl Urol. 2025;14:4033\u201347. https:\/\/doi.org\/10.21037\/tau-2025-581","journal-title":"Transl Androl Urol"},{"key":"1329_CR4","doi-asserted-by":"publisher","unstructured":"Pyrgidis N, Mykoniatis I, Haidich AB, Tirta M, Talimtzi P, Kalyvianakis D, et al. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. BMJ Open. 2021;11:e047396. https:\/\/doi.org\/10.1136\/bmjopen-2020-047396","DOI":"10.1136\/bmjopen-2020-047396"},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jsxmed\/qdae038","volume":"21","author":"D Kalyvianakis","year":"2024","unstructured":"Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Hatzichristou D. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. J Sex Med. 2024;21:533\u20138. https:\/\/doi.org\/10.1093\/jsxmed\/qdae038","journal-title":"J Sex Med"},{"key":"1329_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jsxm.2021.10.007","volume":"19","author":"I Mykoniatis","year":"2022","unstructured":"Mykoniatis I, Pyrgidis N, Zilotis F, Kapoteli P, Fournaraki A, Kalyvianakis D, et al. The effect of combination treatment with low-intensity shockwave therapy and tadalafil on mild and mild-to-moderate erectile dysfunction: a double-blind, randomized, placebo-controlled clinical trial. J Sex Med. 2022;19:106\u201315. https:\/\/doi.org\/10.1016\/j.jsxm.2021.10.007","journal-title":"J Sex Med"},{"key":"1329_CR7","doi-asserted-by":"publisher","unstructured":"Mykoniatis I, Pyrgidis N, Sokolakis I, Ouranidis A, Sountoulides P, Haidich AB, et al. Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2036337. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36337","DOI":"10.1001\/jamanetworkopen.2020.36337"},{"key":"1329_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/andr.70108","volume":"14","author":"A Quistini","year":"2026","unstructured":"Quistini A, Fallara G, Tozzi M, Depalma M, Damiano R, Palmieri A, et al. Comparative efficacy of combination therapy including regenerative therapies versus monotherapy for erectile dysfunction: a systematic review and meta-analysis. Andrology. 2026;14:358\u201367. https:\/\/doi.org\/10.1111\/andr.70108","journal-title":"Andrology"},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/sxmrev\/qeaf032","volume":"13","author":"NN Kim","year":"2025","unstructured":"Kim NN, Wessells H, DiSanto ME, Ferrini MG, Lin G, Pfaus JG, et al. Basic science and translational research: recommendations from the fifth international consultation for sexual medicine (ICSM 2024). Sex Med Rev. 2025;13:483\u2013512. https:\/\/doi.org\/10.1093\/sxmrev\/qeaf032","journal-title":"Sex Med Rev"},{"key":"1329_CR10","doi-asserted-by":"publisher","unstructured":"Alnazari M, Bakhsh A, Abdullah S, Al Qahtani S, Borhan W, Rajih E, et al. Biological implications and therapeutic potential of phosphodiesterase inhibitors: a review. Medicine. 2026;105:e47683. https:\/\/doi.org\/10.1097\/MD.0000000000047683","DOI":"10.1097\/MD.0000000000047683"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01329-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:02:44Z","timestamp":1784584964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-026-01329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":10,"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1038\/s41443-026-01329-1","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}